Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019693 (
HIV
)
170,526
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A list of open trials dealing with
BHC
, wasting, and metabolic abnormalities is presented. Several studies focus on the effects of anti-
HIV
drugs. Other studies are investigating drug therapy, nutrition, and exercise for these conditions. Contact information is provided.
...
PMID:Clinical trials (studies) currently open addressing BHC, wasting and metabolic abnormalities. 1136 60
APOBEC3G (A3G) and related cytidine deaminases are potent inhibitors of retroviruses.
HIV
-1 Vif hijacks the cellular Cul5-E3 ubiquitin ligase to degrade APOBEC3 proteins and render them ineffective against these viruses. Here, we report that
HIV
-1 Vif is a novel zinc-binding protein containing an H-x(5)-C-x(17-18)-C-x(3-5)-H motif that is distinct from other recognized classes of zinc fingers. Zinc-binding stabilized a conserved hydrophobic interface within the
HCCH
motif that is critical for Vif-Cul5 E3 assembly and Vif function. An N-terminal region in the first Cullin repeat of Cul5, which is dispensable for adaptor ElonginC binding, was required for interaction with Vif. This region is the most divergent sequence between Cul2 and Cul5, a factor that may contribute to the selection of Cul5 and not Cul2 by Vif. This is the first example of a zinc-binding substrate receptor responsible for the assembly of a Cullin-RING ligase, representing a new target for antiviral development.
...
PMID:Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. 1653 Jul 99
Vif forms a complex with Elongin B/C, Cullin-5 and Rbx-1 to induce the polyubiquitination and proteasome-mediated degradation of human APOBEC3G (hA3G). These interactions serve as potential targets for anti-
HIV
-1 drug development. We have developed a cell culture-based assay to measure Vif-induced hA3G degradation. The assay is based on alpha-complementation, the ability of beta-galactosidase fragments to complement in trans. hA3G expressed with a fused alpha-peptide was enzymatically active, complemented a coexpressed omega-fragment and could be targeted for degradation by Vif. Vif reduced beta-galactosidase activity in the cell by 10-30-fold. The assay was validated by testing various hA3G and Vif point mutants. The assay accurately detected the effects of D128 in hA3G, and the BC box, Cul5 box and
HCCH
motifs of Vif. The results showed a strict association of Vif biological function with hA3G degradation. These findings support hA3G degradation as a requirement for Vif function. The Vif alpha-complementation assay may be a useful tool for the identification of Vif inhibitors.
...
PMID:Analysis of Vif-induced APOBEC3G degradation using an alpha-complementation assay. 1704 78
Virion infectivity factor (Vif) is an accessory protein encoded by
HIV
-1 and is critical for viral infection of the host CD4(+) T cell population. Vif induces ubiquitination and subsequent degradation of Apo3G, a cytosolic cytidine deaminase that otherwise targets the retroviral genome. Interaction of Vif with the cellular Cullin5-based E3 ubiquitin ligase requires a conserved BC box and upstream residues that are part of the conserved H-(Xaa)(5)-C-(Xaa)(17-18)-C-(Xaa)(3-5)-H (
HCCH
) motif. The
HCCH
motif is involved in stabilizing the Vif-Cullin 5 interaction, but the exact role of the conserved His and Cys residues remains elusive. In this report, we find that full-length
HIV
-1 Vif, as well as a
HCCH
peptide, is capable of binding to zinc with high specificity. Zinc binding induces a conformational change that leads to the formation of large protein aggregates. EDTA reversed aggregation and regenerated the apoprotein conformation. Cysteine modification studies with the
HCCH
peptide suggest that C114 is critical for stabilizing the fold of the apopeptide, and that C133 is located in a solvent-exposed region with no definite secondary structure. Selective alkylation of C133 reduced metal-binding specificity of the
HCCH
peptide, allowing cobalt to bind with rates comparable to that with zinc. This study demonstrates that the
HCCH
motif of
HIV
-1 Vif is a unique metal-binding domain capable of mediating protein-protein interactions in the presence of zinc and adds to a growing list of examples in which metal ion binding induces protein misfolding and/or aggregation.
...
PMID:Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. 1713 31
Human immunodeficiency virus tyoe 1 (HIV-1) Vif counteracts host restriction cytidine deaminase (APOBEC3G) A3G by co-opting the cellular ubiquitin-proteasome machinery. Vif utilizes a viral-specific BC-box to recruit ElonginB-ElonginC and a novel zinc-binding
HCCH
motif to recruit Cullin5 (Cul5) to form an E3 ubiquitin ligase targeting A3G for polyubiquitination and subsequently proteasomal degradation. To determine the structural requirements in
HIV
-1 Vif
HCCH
motif for Cul5 binding and Vif function, we investigated the arrangement of the His and Cys residues, the role of the spacing between them, and the requirement for the conserved residues. Our data demonstrate that exchanging Cys for His and vice versa in the highly conserved Zn-coordinating
HCCH
motif disrupted Vif function and interaction with Cul5. Moreover, the maintenance of both conserved residues and spacing within the
HCCH
motif is critical for Vif function. We have identified a "viral Cul5 box" with consensus Hx2YFxCFx4Phix2APhix7-8Cx5H that is required for Cul5 selection and subsequent A3G degradation. This novel motif may represent a potential new target for anti-viral drug development.
...
PMID:Characterization of a novel Cullin5 binding domain in HIV-1 Vif. 1786 71
The multidomain
HIV
-1 Vif protein recruits several cellular partners to achieve neutralization of the antiviral activity of APOBEC3 proteins. Vif neutralizes APOBEC3G and APOBEC3F predominantly by forming an E3 ubiquitin ligase with Cullin5, ElonginB and ElonginC that targets these proteins for degradation by the ubiquitin-proteasome pathway. Vif associates with the Cullin5-ElonginB-ElonginC complex by binding directly to ElonginC via its SOCS-box motif and to Cullin5 via hydrophobic residues within a zinc-binding region formed by a conserved
HCCH
motif. The
HIV
-1 Vif-Cullin5-ElonginBC complex is then able to ubiquitinate the APOBEC3G factor bound to Vif by its N-terminal domain. In this review, we summarize the current knowledge about the structural determinants of Vif that allow it to interact with cellular and viral partners.
Curr
HIV
Res 2008 Mar
PMID:Advances in the structural understanding of Vif proteins. 1833 56
To define a region(s) in human immunodeficiency virus type 1 (HIV-1) Vif that involves binding to its target APOBEC3G (A3G), we have generated a series of site-specific proviral vif mutants. Of 30 mutants examined, 15 did not grow at all or grew more poorly than wild-type virus in non-permissive cells. Eight clones with N-terminal mutations located outside of the
HCCH
motif and BC-box, which are known to be directly crucial for the degradation of A3G, were chosen from these growth-defective mutants and mainly analyzed in detail for functional activity of their mutant Vif proteins. By single-cycle replication and immunoprecipitation/immunoblotting analyses, mutants designated W21A, S32A, W38A, Y40A, and H43A were demonstrated to hardly or poorly bind to and neutralize A3G. Upon transfection, these mutants produced progeny virions containing much more A3G than wild-type clone. Interestingly, while mutants designated E76A and W79A acted normally to inactivate A3G, they were found to exhibit a Vif-defective phenotype against A3F. Another unique mutant designated Y69A incompetent against both of A3G/F was also identified. Our results here have indicated that at least two distinct regions in the N-terminal half of
HIV
-1 Vif are critical for binding and exclusion of A3G/F.
...
PMID:Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. 1860 11
Virion infectivity factor (Vif) is an accessory protein encoded by
HIV
-1. Vif recruits a Cul5-based ubiquitin ligase that targets APOBEC3G, a host-encoded antiviral enzyme, for proteasomal degradation. The C-terminus of Vif contains a conserved His-X(5)-Cys-X(17-18)-Cys-X(3-5)-His (
HCCH
) motif that binds zinc and interacts with Cul5. In this study, CD spectroscopy, fluorescence spectroscopy, light scattering, and zinc binding assays were used to examine the conformational properties of HCCHp, a 42-amino acid peptide encompassing the
HCCH
motif. A single tryptophan residue was engineered into HCCHp to probe local structural changes induced by zinc binding. Zinc binding increased burial of the Trp residue from solvent and increased tertiary packing. The solvent 2,2,2-trifluoroethanol (TFE) induced the formation of an alpha-helical conformation of HCCHp with a midpoint of 20% (vol/vol) and inhibited zinc-induced aggregation of HCCHp. TFE titration data were sigmoidal, consistent with the cooperative nature of helix formation. Zinc binding to HCCHp in 30% TFE solutions was cooperative and weakened the TFE-induced structure. In 80% TFE solutions this cooperativity was lost, suggesting a mechanism in which monomeric and oligomeric peptide forms display different affinities for zinc. TFE weakened zinc binding to HCCHp by two orders of magnitude relative to the zinc binding affinity measured in aqueous solvent. The data suggest that HCCHp conformation and zinc binding affinity are tightly coupled. We propose that the lack of intrinsic structure in the
HCCH
motif may be important for Vif's function as an E3 ubiquitin ligase adaptor protein.
...
PMID:Conformational analysis of a peptide approximating the HCCH motif in HIV-1 Vif. 1938 67
Virion infectivity factor (Vif) is an
HIV
accessory protein that is essential for the infection of CD4(+) T cells. Vif recruits a Cullin 5 (Cul5)-based ubiquitin ligase that targets a host cytidine deaminase, apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G), for proteasomal degradation. The Vif N-terminus binds APOBEC3G, and the C-terminus interacts with the Cul5-based ubiquitin ligase machinery. Within the C-terminus, a highly conserved H(108)-X(5)-C(114)-X(17-18)-C(133)-X(3-5)-H(139) (
HCCH
) motif binds zinc and is implicated in the Vif-Cul5 interaction. We have employed the biomimetic peptide HCCHp (
HIV
-1 Vif amino acids 101-142) in order to determine the zinc ligands and investigate the role of zinc binding in Cul5 recognition. Using CD spectroscopy, a competitive zinc binding assay, and a light scattering assay, we found that mutation of the conserved His and Cys residues in HCCHp had little effect on secondary structure but reduced zinc binding affinity and altered the aggregation properties of the peptides. X-ray absorption spectroscopy was used to study zinc coordination in wild-type HCCHp. The data are consistent with S(2)N(imid)(2) coordination and strongly suggest that His-108, Cys-114, Cys-133, and His-139 are zinc ligands. Mutation of one or both conserved Cys residues in HCCHp led to a decrease in Cys ligation, and an increase in the number of (N, O) ligands, with noninteger coordination numbers suggesting zinc site heterogeneity. A purified fragment of human Cul5 was found to inhibit zinc-induced aggregation of HCCHp, and pull-down experiments revealed that zinc binding to HCCHp increases the strength of the HCCHp-Cul5 interaction by 8-fold.
...
PMID:Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif. 1958 89
The
HIV
-1 Vif protein (192 residues) is required for
HIV
-1 infection of many target cells. Vif overcomes the anti-viral cellular defense by antagonizing the cellular cytosine deaminase APOBEC-3G through impairing APOBEC-3G production, inhibiting its enzymatic activity and targeting it for degradation. Vif interacts with several viral and cellular molecules, particularly via its C-terminal domain (residues 100-192). The structure of full-length Vif has not yet been determined. The structure of Vif and its domains was studied using computational and experimental methods. Computational predictions resulted in two suggested homology models for the full length protein. Experimental studies have shown that the Vif C-terminal domain is mainly unstructured. Residues 108-139 have mainly random coil conformation in the unbound state. This region includes an
HCCH
Zn(2+)-binding motif that also mediates Vif binding to Cul5, a protein in the E3 ubiquitin ligase complex. The C-terminal domain residues 141-192, which mediate interactions with both ElonginC and Cul5, are intrinsically disordered. This region also includes several phosphorylation sites and regions associated with the ability of Vif to undergo self-oligomerization. The unstructured nature of these regions enables them to interact with several ligands, and probably adopt various conformations as is typical for intrinsically disordered proteins. This was demonstrated by a conformational change induced by Zn(2+) binding to the
HCCH
motif and a conformational change that the C-terminal domain underwent in the presence of dodecylphosphocholine. The only available crystal structure of Vif includes residues 140-155, which are helical when bound to the ElonginBC complex. Overall, empirical structures, predictions and other experimental data for Vif did not always indicate the same degree or type of structure for any given region. This ambiguity is likely to be the tenet of structurally unfolded proteins, which have the propensity to adopt a multitude of biologically relevant and active conformations.
...
PMID:Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure. 2045 Apr 85
1
2
Next >>